
==== Front
Mol Metab
Mol Metab
Molecular Metabolism
2212-8778
Elsevier

S2212-8778(24)00154-6
10.1016/j.molmet.2024.102023
102023
Corrigendum
Corrigendum to “Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity” [Mol Metab 78 (2023) 101801]
Friedrichsen Martin Haljeta mfrc@novonordisk.com
1⁎
Endahl Lars 1
Kreiner Frederik Flindt 1
Goldwater Ronald 2
Kankam Martin 3
Toubro Søren 1
Nygård Sune Boris 1
1 Novo Nordisk A/S, Søborg, Denmark
2 Parexel International, Baltimore, MD, USA
3 Altasciences Clinical Kansas, Overland Park, KS, USA
⁎ Corresponding author. Dr Martin Haljeta Friedrichsen, Novo Nordisk A/S, Vandtårnsvej 108, Suborn, DK-2860, Denmark. mfrc@novonordisk.com
05 9 2024
11 2024
05 9 2024
89 102023© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
==== Body
pmcIn the original version of this manuscript, Table S2B was inadvertently omitted from the Supplementary Data. This table provides baseline characteristics data by dose level, for the multiple ascending dose trial. The corrected supplementary file, now including Table S2B, is available with this corrigendum. Please note that all data, findings, and conclusions of this study have not been affected by the corrigendum. The authors would like to apologise for any inconvenience caused.

Appendix A Supplementary data

The following is/are the supplementary data to this article:Multimedia component 1

Multimedia component 1

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2024.102023.
